The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

medigen-usa.com

Stage

Incubator/Accelerator | Alive

About Medigen

MEDIGEN, INC. Medigen, Inc. is a biotechnology company that specializes in biomedical research and consulting services in the areas of infectious diseases, cancer, and human gene therapy. Our expertise is emerging human diseases and biodefense vaccines. Medigen, Inc. strives to serve clients by transforming the promise of science and biotechnology into information, vaccines, and therapies that have the power to restore health and save lives. We apply methods of molecular biology, protein engineering, and molecular virology for development of conceptually new vaccine approaches.

Medigen Headquarter Location

Frederick, Maryland, 21701,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Medigen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Medigen is included in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Medigen Patents

Medigen has filed 17 patents.

The 3 most popular patent topics include:

  • Animal virology
  • Hepatology
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/21/2017

7/13/2021

Virus families, Animal virology, Molecular biology, Viral diseases, Viral plant pathogens and diseases

Grant

Application Date

11/21/2017

Grant Date

7/13/2021

Title

Related Topics

Virus families, Animal virology, Molecular biology, Viral diseases, Viral plant pathogens and diseases

Status

Grant

Latest Medigen News

Medigen posts NT$1.41bn net profit

Mar 1, 2022

Medigen posts NT$1.41bn net profit By Kao Shih-ching / Staff reporter Medigen Vaccine Biologics Corp (高端疫苗) yesterday reported net profit of NT$1.41 billion (US$50.3 million) for last year and its board of directors approved a plan to distribute a stock dividend of NT$5 per share, a company regulatory filing showed. The company turned a profit for the first time last year, thanks to sales of 5 million doses of its COVID-19 vaccine to the Ministry of Health and Welfare, and a government subsidy of NT$470 million for human testing. Medigen, which began selling its COVID-19 vaccine in the second half of last year after being granted an emergency use authorization in July, reported that revenue expanded 298-fold to NT$3.28 billion, up from NT$11 million in 2020. A vial of Medigen Vaccine Biologics Corp’s COVID-19 vaccine is pictured in Taipei on Jan. 20. Photo: Tsai Szu-pei, Taipei Times Earnings per share were NT$6.65 last year, compared with losses per share of NT$3.61 in 2020, the company said. The dividend payout would be subject to shareholders’ approval at an annual general meeting on June 30, it said. The board of directors also approved a proposal to raise funds by issuing 7 million new common shares, as the company aims to continue expanding production capacity, Medigen said. The company expects to raise NT$1.75 billion via the new share issuance and obtain another NT$1.75 billion via a new bond issuance, it said. Medigen expects to receive more international orders for its COVID-19 vaccine this year and aims to produce 100 million doses this year, it said. Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

Medigen Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Medigen Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.